Cyclerion appoints CEO Peter Hecht as interim CFO during CFO's maternity leave

Cyclerion Therapeutics, Inc.

Peter M. Hecht, CEO, appointed Interim CFO effective October 27, 2021 while Anjeza Gjino is on maternity leave.
Upon Ms. Gjino's return, she will resume her CFO role and Dr. Hecht will return to CEO duties.
Other officers have assumed some of Ms. Gjino's responsibilities during her absence.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Peter M. Hecht

Interim Chief Financial Officer

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2021-10-27
Filed: October 28, 2021, 7:59 PM ET

On October 27, 2021, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) temporarily appointed Peter M. Hecht, Ph.D., as Interim Chief Financial Officer (principal financial and accounting officer) of the Company while Anjeza Gjino is on maternity leave.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter M. Hecht was appointed as Interim Chief Financial Officer at Cyclerion Therapeutics, Inc..

Action: temporarily appointed
Role: Interim Chief Financial Officer

Exact text from the filing

On October 27, 2021, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) temporarily appointed Peter M. Hecht, Ph.D., as Interim Chief Financial Officer (principal financial and accounting officer) of the Company while Anjeza Gjino is on maternity leave.

View on SEC.gov

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-21-035774

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.